Markets

Cytokinetics, Incorporated (CYTK) in Focus: Stock Surges 16.2% - Tale of the Tape

Cytokinetics, Incorporated ( CYTK ) was a big mover last session, as the company saw its shares rise over 16% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 30.7% since Oct 10, 2014.

The biotechnology company has seen one positive revision in the past one month, while its Zacks Consensus Estimate moved higher over the same time frame, suggesting that more solid trading could be ahead for Cytokinetics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Cytokinetics currently carries a Zacks Rank #1 (Strong Buy) while its Earnings ESP is 0.00%.

Investors interested in the biotechnology industry may also consider other well-placed stocks such as Affymetrix Inc. ( AFFX ), Agenus Inc. ( AGEN ) and AMAG Pharmaceuticals, Inc. ( AMAG ). All these stocks carry the same Zacks Rank as Cytokinetics.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CYTOKINETCS INC (CYTK): Free Stock Analysis Report

AFFYMETRIX INC (AFFX): Free Stock Analysis Report

AGENUS INC (AGEN): Free Stock Analysis Report

AMAG PHARMA INC (AMAG): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AGEN CYTK

Other Topics

Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More